BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 33452711)

  • 1. Systematic review of phase-I/II trials enrolling refractory and recurrent Ewing sarcoma: Actual knowledge and future directions to optimize the research.
    Felix A; Berlanga P; Toulmonde M; Landman-Parker J; Dumont S; Vassal G; Le Deley MC; Gaspar N
    Cancer Med; 2021 Mar; 10(5):1589-1604. PubMed ID: 33452711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase-II trials in osteosarcoma recurrences: A systematic review of past experience.
    Omer N; Le Deley MC; Piperno-Neumann S; Marec-Berard P; Italiano A; Corradini N; Bellera C; Brugières L; Gaspar N
    Eur J Cancer; 2017 Apr; 75():98-108. PubMed ID: 28219023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
    London WB; Bagatell R; Weigel BJ; Fox E; Guo D; Van Ryn C; Naranjo A; Park JR
    Cancer; 2017 Dec; 123(24):4914-4923. PubMed ID: 28885700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial.
    Andreou D; Ranft A; Gosheger G; Timmermann B; Ladenstein R; Hartmann W; Bauer S; Baumhoer D; van den Berg H; Dijkstra PDS; Dürr HR; Gelderblom H; Hardes J; Hjorth L; Kreyer J; Kruseova J; Leithner A; Scobioala S; Streitbürger A; Tunn PU; Wardelmann E; Windhager R; Jürgens H; Dirksen U;
    Clin Orthop Relat Res; 2020 Feb; 478(2):290-302. PubMed ID: 31580267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma.
    Villablanca JG; Ji L; Shapira-Lewinson A; Marachelian A; Shimada H; Hawkins RA; Pampaloni M; Lai H; Goodarzian F; Sposto R; Park JR; Matthay KK
    Pediatr Blood Cancer; 2018 May; 65(5):e26940. PubMed ID: 29350464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigational therapies for Ewing sarcoma: a search without a clear finding.
    Vornicova O; Bar-Sela G
    Expert Opin Investig Drugs; 2016 Jun; 25(6):679-86. PubMed ID: 26988130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
    Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway.
    van Maldegem AM; Bovée JV; Peterse EF; Hogendoorn PC; Gelderblom H
    Eur J Cancer; 2016 Jan; 53():171-80. PubMed ID: 26765686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.
    Amoroso L; Castel V; Bisogno G; Casanova M; Marquez-Vega C; Chisholm JC; Doz F; Moreno L; Ruggiero A; Gerber NU; Fagioli F; Hingorani P; Melcón SG; Slepetis R; Chen N; le Bruchec Y; Simcock M; Vassal G
    Eur J Cancer; 2020 Aug; 135():89-97. PubMed ID: 32554315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.
    Choy E; Butrynski JE; Harmon DC; Morgan JA; George S; Wagner AJ; D'Adamo D; Cote GM; Flamand Y; Benes CH; Haber DA; Baselga JM; Demetri GD
    BMC Cancer; 2014 Nov; 14():813. PubMed ID: 25374341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ewing sarcoma: investigational mono- and combination therapies in clinical trials.
    Gartrell J; Rodriguez-Galindo C
    Expert Opin Investig Drugs; 2021 Jun; 30(6):653-663. PubMed ID: 33870845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.
    Italiano A; Mir O; Mathoulin-Pelissier S; Penel N; Piperno-Neumann S; Bompas E; Chevreau C; Duffaud F; Entz-Werlé N; Saada E; Ray-Coquard I; Lervat C; Gaspar N; Marec-Berard P; Pacquement H; Wright J; Toulmonde M; Bessede A; Crombe A; Kind M; Bellera C; Blay JY
    Lancet Oncol; 2020 Mar; 21(3):446-455. PubMed ID: 32078813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.
    Subbiah V; Braña I; Longhi A; Boni V; Delord JP; Awada A; Boudou-Rouquette P; Sarantopoulos J; Shapiro GI; Elias A; Ratan R; Fernandez C; Kahatt C; Cullell-Young M; Siguero M; Zeaiter A; Chawla SP
    Clin Cancer Res; 2022 Jul; 28(13):2762-2770. PubMed ID: 35486638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials.
    Livingston JA; Hess KR; Naing A; Hong DS; Patel S; Benjamin RS; Ludwig JA; Conley A; Herzog CE; Anderson P; Meric-Bernstam F; Kurzrock R; Subbiah V
    Oncotarget; 2016 Sep; 7(39):64421-64430. PubMed ID: 27486883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome of patients with recurrent or refractory localized Ewing's sarcoma family of tumors: A retrospective report from the Japan Ewing Sarcoma Study Group.
    Umeda K; Miyamura T; Yamada K; Sano H; Hosono A; Sumi M; Okita H; Kumamoto T; Kawai A; Hirayama J; Jyoko R; Sawada A; Nakayama H; Hosoya Y; Maeda N; Yamamoto N; Imai C; Hasegawa D; Chin M; Ozaki T;
    Cancer Rep (Hoboken); 2021 Jun; 4(3):e1329. PubMed ID: 33452866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A meta-analytic evaluation of the correlation between event-free survival and overall survival in randomized controlled trials of newly diagnosed Ewing sarcoma.
    Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
    BMC Cancer; 2020 May; 20(1):379. PubMed ID: 32370741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective Analysis of Outcomes of Patients with Relapsed, Refractory and Metastatic Sarcomas who have received Metronomic Chemotherapy.
    Devadas SK; Banavali S
    Gulf J Oncolog; 2019 May; 1(30):22-28. PubMed ID: 31242978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.
    Fox E; Patel S; Wathen JK; Schuetze S; Chawla S; Harmon D; Reinke D; Chugh R; Benjamin RS; Helman LJ
    Oncologist; 2012; 17(3):321. PubMed ID: 22363068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential approaches to the treatment of Ewing's sarcoma.
    Yu H; Ge Y; Guo L; Huang L
    Oncotarget; 2017 Jan; 8(3):5523-5539. PubMed ID: 27740934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.